BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive sub-type of breast cancer. Dasatinib and bosutinib are FDA-approved Src/Abl kinase inhibitor drugs. Dasatinib potently inhibits the proliferation of many TNBC cell lines. MATERIALS AND METHODS: The cell viability/proliferation for a panel of 4 TNBC cell lines was measured by detection of cellular ATP levels and cell numbers were directly determined by automated cell counting. RESULTS: Bosutinib (≤1 μM) had little to no inhibitory activity on cell viability/proliferation, while dasatinib-alone generated potent IC50 values of <100 nM. Combination treatment of cells with both dasatinib and bosutinib resulted in reduced efficacy of dasatinib in all four cell lines, with two of them displaying a dramatic loss of efficacy. Direct cell counting confirmed that bosutinib enhanced cell proliferation in the presence of dasatinib. CONCLUSION: Bosutinib potently reduced the in vitro anti-proliferative efficacy of dasatinib in TNBC cell lines. We, hereby, report on a novel drug-induced loss in dasatinib sensitivity.
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive sub-type of breast cancer. Dasatinib and bosutinib are FDA-approved Src/Abl kinase inhibitor drugs. Dasatinib potently inhibits the proliferation of many TNBC cell lines. MATERIALS AND METHODS: The cell viability/proliferation for a panel of 4 TNBC cell lines was measured by detection of cellular ATP levels and cell numbers were directly determined by automated cell counting. RESULTS:Bosutinib (≤1 μM) had little to no inhibitory activity on cell viability/proliferation, while dasatinib-alone generated potent IC50 values of <100 nM. Combination treatment of cells with both dasatinib and bosutinib resulted in reduced efficacy of dasatinib in all four cell lines, with two of them displaying a dramatic loss of efficacy. Direct cell counting confirmed that bosutinib enhanced cell proliferation in the presence of dasatinib. CONCLUSION:Bosutinib potently reduced the in vitro anti-proliferative efficacy of dasatinib in TNBC cell lines. We, hereby, report on a novel drug-induced loss in dasatinib sensitivity.
Authors: Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol Journal: J Clin Invest Date: 2011-07 Impact factor: 14.808
Authors: Louis J Lombardo; Francis Y Lee; Ping Chen; Derek Norris; Joel C Barrish; Kamelia Behnia; Stephen Castaneda; Lyndon A M Cornelius; Jagabandhu Das; Arthur M Doweyko; Craig Fairchild; John T Hunt; Ivan Inigo; Kathy Johnston; Amrita Kamath; David Kan; Herbert Klei; Punit Marathe; Suhong Pang; Russell Peterson; Sidney Pitt; Gary L Schieven; Robert J Schmidt; John Tokarski; Mei-Li Wen; John Wityak; Robert M Borzilleri Journal: J Med Chem Date: 2004-12-30 Impact factor: 7.446
Authors: Nagathihalli S Nagaraj; J Joshua Smith; Frank Revetta; M Kay Washington; Nipun B Merchant Journal: Mol Cancer Ther Date: 2010-08-03 Impact factor: 6.261
Authors: Richard S Finn; Judy Dering; Charles Ginther; Cindy A Wilson; Padraic Glaspy; Nishan Tchekmedyian; Dennis J Slamon Journal: Breast Cancer Res Treat Date: 2007-02-01 Impact factor: 4.872
Authors: Peter S Hammerman; Martin L Sos; Alex H Ramos; Chunxiao Xu; Amit Dutt; Wenjun Zhou; Lear E Brace; Brittany A Woods; Wenchu Lin; Jianming Zhang; Xianming Deng; Sang Min Lim; Stefanie Heynck; Martin Peifer; Jeffrey R Simard; Michael S Lawrence; Robert C Onofrio; Helga B Salvesen; Danila Seidel; Thomas Zander; Johannes M Heuckmann; Alex Soltermann; Holger Moch; Mirjam Koker; Frauke Leenders; Franziska Gabler; Silvia Querings; Sascha Ansén; Elisabeth Brambilla; Christian Brambilla; Philippe Lorimier; Odd Terje Brustugun; Aslaug Helland; Iver Petersen; Joachim H Clement; Harry Groen; Wim Timens; Hannie Sietsma; Erich Stoelben; Jürgen Wolf; David G Beer; Ming Sound Tsao; Megan Hanna; Charles Hatton; Michael J Eck; Pasi A Janne; Bruce E Johnson; Wendy Winckler; Heidi Greulich; Adam J Bass; Jeonghee Cho; Daniel Rauh; Nathanael S Gray; Kwok-Kin Wong; Eric B Haura; Roman K Thomas; Matthew Meyerson Journal: Cancer Discov Date: 2011-06 Impact factor: 39.397
Authors: Jiannong Li; Uwe Rix; Bin Fang; Yun Bai; Arthur Edwards; Jacques Colinge; Keiryn L Bennett; Jingchun Gao; Lanxi Song; Steven Eschrich; Giulio Superti-Furga; John Koomen; Eric B Haura Journal: Nat Chem Biol Date: 2010-02-28 Impact factor: 15.040
Authors: James S Duncan; Martin C Whittle; Kazuhiro Nakamura; Amy N Abell; Alicia A Midland; Jon S Zawistowski; Nancy L Johnson; Deborah A Granger; Nicole Vincent Jordan; David B Darr; Jerry Usary; Pei-Fen Kuan; David M Smalley; Ben Major; Xiaping He; Katherine A Hoadley; Bing Zhou; Norman E Sharpless; Charles M Perou; William Y Kim; Shawn M Gomez; Xin Chen; Jian Jin; Stephen V Frye; H Shelton Earp; Lee M Graves; Gary L Johnson Journal: Cell Date: 2012-04-13 Impact factor: 41.582